Loading
A phase 1/2 trial of SHR-A2102, Adebrelimab, Cetuximab in head and neck squamous cell carcinoma, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting.
A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer is a phase 1/2 interventional study registered as NCT07059221 by Suzhou Suncadia Biopharmaceuticals Co., Ltd., with 210 participants planned, started 2025-07-11 and due to reach its primary completion in 2027-03. Interventions recorded: SHR-A2102, Adebrelimab, Cetuximab, SHR-9839(sc), Carboplatin / Cisplatin. Conditions listed: Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.
Shares SHR-A2102, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Cisplatin.
Shares SHR-A2102, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Cisplatin.
Shares SHR-A2102, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Cisplatin.
Shares SHR-A2102, Adebrelimab, Cetuximab, Jiangsu Hengrui Pharmaceuticals.
Shares SHR-A2102, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Monoclonal antibodies.
Shares Adebrelimab, Cetuximab, Jiangsu Hengrui Pharmaceuticals, Cisplatin.
Shares SHR-A2102, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Monoclonal antibodies.
Shares Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Cisplatin, Monoclonal antibodies.